Gastro-oesophageal reflux disease in Asia

被引:115
作者
Goh, KL [1 ]
Chang, CS
Fock, KM
Ke, MY
Park, HJ
Lam, SK
机构
[1] Univ Malaya, Fac Med, Dept Med, Kuala Lumpur 50603, Malaysia
[2] Taichung Vet Gen Hosp, Taichung, Taiwan
[3] Changi Gen Hosp, Singapore, Singapore
[4] Beijing Union Med Coll Hosp, Beijing, Peoples R China
[5] Yonsei Univ, Seoul 120749, South Korea
[6] Univ Hong Kong, Hong Kong, Hong Kong, Peoples R China
关键词
Asia; cisapride; disease management; gastro-oesophageal reflux disease; histamine H-2-receptor antagonists; prokinetic drugs; proton pump inhibitors;
D O I
10.1046/j.1440-1746.2000.02148.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Gastro-oesophageal reflux disease (GORD) occurs more frequently in Europe and North America than in Asia but its prevalence is now increasing in many Asian countries. Many reasons have been given for the lower prevalence of GORD in Asia. Low dietary fat and genetically determined factors, such as body mass index and maximal acid output, may be important. Other dietary factors appear to be less relevant. Increased intake of carbonated drinks or aggravating medicines may influence the increasing rates of GORD in some Asian countries but no strong evidence links other factors, such as the age of the population, smoking or alcohol consumption, to GORD. The management of GORD in Asia is similar to that in Europe and North America but the lower incidence of severe oesophagitis in Asia may alter the approach slightly. Also, because Asians tend to develop stomach cancer at an earlier age, endoscopy is used routinely at an earlier stage of investigation. Gastro-oesophageal reflux disease is essentially a motility disorder, so short-term management of the disease can usually be achieved using prokinetic agents (or histamine (H-2)-receptor antagonists). More severe and recurrent GORD may require proton pump inhibitors (PPI) or a combination of prokinetic agents and PPI. The choice of long-term treatment may be influenced by the relative costs of prokinetic agents and PPI. (C) 2000 Blackwell Science Asia Pty Ltd.
引用
收藏
页码:230 / 238
页数:9
相关论文
共 71 条
  • [61] Update on the pathophysiology and management of gastro-oesophageal reflux disease: The role of prokinetic therapy
    Tytgat, GNJ
    Janssens, J
    Reynolds, JC
    Wienbeck, M
    [J]. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 1996, 8 (06) : 603 - 611
  • [62] THE CLINICAL USE OF CISAPRIDE IN GASTROESOPHAGEAL REFLUX DISEASE, WITH PARTICULAR FOCUS ON THE LONG-TERM TREATMENT ASPECTS
    TYTGAT, GNJ
    [J]. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1995, 30 : 39 - 43
  • [63] GASTROESOPHAGEAL REFLUX AND HIATAL HERNIA - COMPLICATIONS AND THERAPY
    URSCHEL, HC
    PAULSON, DL
    [J]. JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 1967, 53 (01) : 21 - &
  • [64] A COMPARISON OF 5 MAINTENANCE THERAPIES FOR REFLUX ESOPHAGITIS
    VIGNERI, S
    TERMINI, R
    LEANDRO, G
    BADALAMENTI, S
    PANTALENA, M
    SAVARINO, V
    DIMARIO, F
    BATTAGLIA, G
    MELA, GS
    PILOTTO, A
    PLEBANI, M
    DAVI, G
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (17) : 1106 - 1110
  • [65] Wang T H, 1978, Taiwan Yi Xue Hui Za Zhi, V77, P44
  • [66] Helicobacter pylori infection and atrophic gastritis - A case-control study in a rural town of Japan
    Watanabe, Y
    Ozasa, K
    Higashi, A
    Hayashi, K
    Mizuno, S
    Mukai, M
    Inokuchi, H
    Miki, K
    Kawai, K
    [J]. JOURNAL OF CLINICAL GASTROENTEROLOGY, 1997, 25 (01) : 391 - 394
  • [67] WENDL B, 1994, ALIMENT PHARM THER, V8, P283
  • [68] Wilson LJ, 1996, GASTROENTEROLOGY, V110, pA296
  • [69] WRIGHT RA, 1979, DIGEST DIS SCI, V24, P311, DOI 10.1007/BF01296546
  • [70] Erosive esophagitis and Barrett's esophagus in Taiwan - A higher frequency than expected
    Yeh, C
    Hsu, CT
    Ho, AS
    Sampliner, RE
    Fass, R
    [J]. DIGESTIVE DISEASES AND SCIENCES, 1997, 42 (04) : 702 - 706